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Purpose: Fifty-one consecutive patients with premature lower extremity atherosclerosis 
were prospectively evaluated for atherogenic risk factors and primary or acquired 
hypercoagulability, which might contribute to early ischemia nd revascularization failure. 
Methods: Laboratory tests included plasma assays of (1) natural anticoagulants (NAC), 
lipoprotein (a) (Lp[a]), and anticardiolipin antibodies, and (2) fibrinolytic activators and 
inhibitors at baseline and stimulated after 20 minutes of upper extremity venous occlusion. 
Results: Forty-six (90%) of these 51 patients had laboratory abnormalities. One or more 
NAC deficiencies were found in 15 (30~ patients and included antithrombin III (n = 5), 
protein C (n = 8), protein S (n = 4), and heparin cofactor II (n = 2). Hypofibrinolysis 
was identified as a deficiency of stimulated tissue plasminogen activator in 22 (45%) 
patients and elevated plasminogen activator inhibitor-1 (PAI-1) in 29 (59%). Elevated 
Lp(a) was found in 43 (86%) patients. Five (10%) patients had anticardiolipin antibodies. 
Ten patients had combined NAC deficiency and hypofibrinolysis. Five (10%) patients had 
no abnormality. NAC deficiencies, especially protein C deficiency, were associated with 
acute ischemia (p < 0.01), prior vascular intervention (p < 0.01), an increasing number 
of total vascular procedures (p < 0.01), and major amputation (p < 0.01). PAI-1 was 
associated with a history of heart disease (p < 0.05) and prior vascular procedures 
(p < 0.05). Elevated Lp(a) was associated with elevated PAI-1 (p < 0.05). Retesting in 
20 patients uggested that 80% of NAC deficiencies were acquired, but abnormalities 
persisted in 66% of patients with elevated PAI-1 and in 93% of those with elevated Lp(a). 
Conclusions: These data strongly support the hypothesis that the convergence of 
atherogeuic risk factors and hypercoagulability play an important role in early ischemia 
and poor results reported for lower extremity vascular procedures inyoung adults. (J VAsc 
SURG 1996;23:36-45.) 
Atherosclerotic arterial occlusive disease is recog- 
nized as the major cause of lower extremity ischemia 
in young adults. ~-5 Unlike the relatively slow pro- 
gression of atherosclerosis in the elderly, premature 
atherosclerosis in young patients has been character- 
ized as a "virulent" disease.~ Recent studies agree that 
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younger patients with lower extremity arterial occlu- 
sive disease have rapid deterioration to severe isch- 
emia, an increased risk of early vascular reconstructive 
failure, and a high incidence-of  major limb 
amputation, ls It has been proposed that unique 
hereditary or acquired risk factors, in addition to 
typical cardiovascular risk factors, distinguish the 
clinical course of  atherosclerosis in the young from 
that seen in the elderly. 
Among possible unique characteristics distin- 
guishing atherosclerosis in younger and older pa- 
tients are the so-called hypercoagulable states, ~2 In 
the past, hypercoagulability was associated primarily 
with venous thrombosis but has become increasingly 
recognized in arterial thrombosis and embolism.~~ 
Hypercoagulability can exist in latent forms identi- 
fiable by various plasma markers or may under 
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ill-defined circumstances precipitate a clinical syn- 
drome of episodic thrombotic events properly 
termed ahypercoagulable state. Such hypercoagulable 
states have been related to a number of primary or 
acquired deficiencies of regulatory anticoagulant 
plasma proteins (natural anticoagulants), defective or 
inhibited fibrinolytic activity (hypofibrinolysis), pro- 
coagulant autologous antibodies (anticardiolipin an- 
tibodies), and increased platelet aggregability. 1~
Additionally, high levels of lipoprotein (a) (Lp[a]) 
may both be an independent risk factor for athero- 
sclerosis and play a role in the inhibition of fibrino- 
lysis) s'14 In young patients with lower extremity 
ischemia, hypercoagulability has been shown to have 
a high predictive value for early bypass failure and 
major amputation, s-8
It was the possible association of hypercoagula- 
bility and the progression of lower extremity athero- 
sclerosis that prompted this prospective laboratory 
evaluation. The goals of this study were to demon- 
strate the incidence of markers associated with 
atherogenesis and hypercoagulability in nonselected, 
young patients with symptoms of premature lower 
extremity atherosclerosis and to associate any abnor- 
malities with clinical stages of peripheral arterial 
occlusive disease. 
PATIENTS AND METHODS 
Patient selection. Between September 1991 and 
March 1995, 51 consecutive young patients referred 
with premature lower extremity atherosclerosis were 
prospectively evaluated for plasma markers associated 
with atherogenesis and hypercoagulability. All 51 
patients included in the study had the onset of lower 
extremity ischemic symptoms before age 45 years. 
Patients with arterial trauma, thromboembolism, or 
other nonatherosclerotic causes of lower extremity 
arterial occlusive disease were excluded. Although 
patients were.prospectively valuated according to 
laboratory protocol, neither their past nor subse- 
quent vascular surgical treatment followed a prede- 
termined treatment protocol. Definitions, terminol- 
ogy, and reporting conventions conform to recom- 
mendations for reports dealing with lower extremity 
ischemia from the Ad Hoc Committee on Reporting 
Standards of the Joint Council of the Vascular 
Societies.~5 This study was conducted with informed 
consent and approved by Institutional Review 
Boards of the University of South Carolina School of 
Medicine and affiliated hospitals. 
Data collection. Retrospectively collected clini- 
cal data included demographic characteristics; car- 
diovascular risk factors such as history of smoking, 
diabetes mellitus, hypertension, hyperlipidemia, re- 
nal insufficiency, family history, coronary artery 
disease, cardiac intervention(s), and stroke; history of 
deep vein thrombophlebitis or pulmonary embolism; 
clinical or vascular laboratory assessment of lower 
extremity ischemia; prior peripheral vascular inter- 
vention(s) or amputation(s); and routine laboratory 
studies of cholesterol, triglycerides, prothrombin 
time (PT), partial thromboplastin time (PTT), fi- 
brinogen, and platelets. Prospectively collected clini- 
cal data included clinical and vascular laboratory 
assessment of concurrent lower extremity ischemia 
and subsequent peripheral vascular interventions or
amputations. Laboratory determination of plasma 
abnormalities a sociated with hypercoagulability in- 
cluded natural anticoagulants: antithrombin III, 
protein C, protein S, and heparin cofactor II; baseline 
and stimulated fibrinolytic activity: tissue plasmino- 
gen activator (t-PA) and plasminogen activator 
inhibitor-1 (PAI-1); Lp(a); and anticardiolipin anti- 
bodies. Determination of factor VII was performed 
for patients receiving warfarin. Efforts were made to 
repeat laboratory tests that had abnormal results at a 
later, more stable stage of each patient's vascular 
disease to determine whether observed abnormalities 
were primary or acquired. Retesting was preferably 
delayed at least 3 months in patients having vascular 
intervention, surgery, or acute arterial or venous 
thrombotic events. Normal controls were performed 
concurrently throughout the study. Normal ranges 
and number of patients tested for each laboratory 
determinant are shown in Table I. 
Laboratory evaluation. The antithrombin III 
functional assay (American Dade, Miami, Fla.) was 
based on the principle that antithrombin III com- 
plexed with reagent heparin inhibits a known amount 
of thrombin. After incubation with a sample of 
patient plasma, residual (noninhibited) thrombin 
hydrolyzes a thrombin-specific chromogenic sub- 
strate, D-phenylalanine-proline-arginine- 5-amidoiso- 
phthalic acid, to release afluorescent ester that can be 
measured by spectrophotometry. The amidolytic 
activity of the residual thrombin is inversely propor- 
tional to the amount of antithrombin III in the 
patient sample, which can be quantitated by com- 
parison to a standard. 16Heparin cofactor II was 
determined by residual antithrombire activity in a. 
sample of patient plasma after reagent throm- 
bin/antithrombin incubation for 300 seconds) 7 
Protein C activity was determined by a coagulo- 
metric method based on the activation of protein C 
in a sample of patient plasma with a specifc snake 
(Agkistrodon contotrix) venom activator (American 
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Table I. Laboratory evaluation of potential hypercoagulable states in 51 young patients with 
premature lower extremity atherosclerosis 
Normal range Patients tested (no.) 
Natural anticoagulants 
Antithrombin III (function) 70%- 110% 51 
Protein C (function) 70%-110% 51 
Protein C/factor VII ratio > 0.69 
Protein S (function) 70%-110% 50 
Protein S/factor VII ratio > 0.69 
Heparin cofactor II (function) 70%-110% 38 
Fibrinolytic system 
Tissue plasminogen activator (antigen) 
Baseline t-PA > 1.2 IU/ml 49 
20 min venous occlusion 4 X increase 49 
Plasminogen activator inhibitor-1 (antigen) 
Baseline PAI-1 < 16 IU/ml 49 
20 min venous occlusion < 16 IU/ml 49 
LP(a) 50 
White < 110 mg/L 
Black < 200 mg/L 
Anticardiolipin antibodies Negative 50 
Bioproduct Co., Parsipanny, N.J.). Activated protein 
C inhibits factors V and VIII contained in protein 
C-deficient plasma. Inhibition of factors V and VIII 
prolongs the PTI', which is proportional to the 
amount of protein C in the patient sample.'8 Protein 
S activity is proportional to prolongation of the PT 
in a protein S-deficient plasma to which a diluted 
sample of patient plasma was added. In this deter- 
mination, reagent bovine thromboplastin (American 
Dade) was used to measure the PT. ~9 Protein C and 
protein S are vitamin K-dependent natural antico- 
agulants. Thus patients receiving warfarin therapy 
were also tested for factor VII levels. Factor VII 
activity was measured by nephelometric assay after 
incubation with tissue thromboplastin and quanti- 
rated by comparison of turbidity with controls 
(Sigma Chemical Co., St. Louis, Mo.). 2~ Protein 
C/factor VII or protein S/factor VII ratios less than 
0.69 support he diagnosis of protein C or protein S 
deficiency in patients receiving warfarin. 
Assays of t-PA and PAI-1 activity were deter- 
mined with chromogenic substrates by enzyme- 
linked immunosorbant assay (ELISA) (Sigma 
Chemical Co.). 21 These assays were performed pref- 
erably in the morning with the patient rested to avoid 
diurnal and exercise variations. Baseline samples of 
patient plasma were collected by a nontraumatic 
venipuncture, usually from the dorsum of the domi- 
nant hand. A sphygmomanometer was then applied 
to the upper arm and inflated to a pressure at midlevel 
between systolic and diastolic arterial pressures. After 
20 minutes of venous occlusion, stimulated samples 
were collected from the same venipuncture site, 
which had been maintained patent with normal saline 
solution. Plasma t-PA activity was assayed by incu- 
bating samples with plasminogen activator eagent 
(American Diagnostics, New Haven, Conn.) for 15 
minutes, at which time fibrin was added to stop t-PA 
reactivity. Absorbance differences between samples 
and controls were then measured by ELISA spectro- 
photometry at 480 nm. PAI-1 was determined by 
residual t-PA activity in patient plasma nd controls 
after 135 minutes incubation with plasminogen 
activator reagent and PAI-l-depleted plasma. 
Lp(a) was assayed by use of microstrips coated 
with high-affinity purified anti-apo (a) antibodies 
(American Diagnostics), to which control and dupli- 
cate patient plasma samples were added and incu- 
bated for 60 minutes. Next, conjugated anti-Lp(a) 
immunoglobulin G antibody was added and incu- 
bated 15 min. Absorbance was then read by ELISA 
spectrophotometry at 492 nm in a microplate. 22It is 
widely accepted that 300 mg/L is the upper limit of 
normal for Lp(a). 13,14 Controls in this laboratory sug- 
gested the need for the more stringent definitions and 
racial variations for Lp(a) levels shown in Table I. 
Anticardiolipin antibodies were measured by 
ELISA (American Diagnostics). Samples of stan- 
dard, control, and patient plasma were incubated 
with cardiolipin in microcuvettes for 60 min. Con- 
jugated immunoglobulin G, A, and M were then 
added for colorimetric development a 405 nm by 
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ELISA spectrophotometry. Anticardiolipin antibod- 
ies were determined from the standard curve and 
controls. 2s 
Statistical analysis. Data were entered into a 
case report file created on Epi-Info 6.0 (Centers for 
Disease Control, Atlanta) and verified for accuracy. 
These data were then transported to the mainframe 
computer at the University of South Carolina for 
analysis with SPSS-X (SPSS-X Inc., Chicago, Ill.). 
Categorical variables were assessed by chi-square or 
Fisher's exact test where expected cell frequencies 
were n < 5. Interval variables were assessed by 
one-way analysis of variance and t tests. Statistical 
significance was defined atp < 0.05. 
RESULTS 
Patient population. Of the 51 patients in this 
study, 30 (59%) were men, and 21 (41%) were 
women; 31 (61%) were white and 20 (39%) were 
black. The mean age at the onset of lower extremity 
ischemic symptoms was 41 years (range 29 to 45 
years). The mean age at evaluation i  this study was 
45 years (range 29 to 53 years). Cardiovascular risk 
factors included current smoking in 34 (67%) and 
former smoking in 15 (29%) patients (96% total 
smokers with a mean 22.5 pack-years moking 
history). Diabetes mellitus was found in 17 (33%) 
patients; nine were insulin dependent and eight were 
non-insulin dependent. Hypertension was present in 
29 (56%), hyperlipidemia n 35 (80%), chronic 
kidney failure in 4 (8%), and a family history of 
cardiovascular disease in 31 ( 61%) patients. Eighteen 
(35%) patients had a prior myocardial infarction, and 
13 underwent coronary artery revascularization. 
Four (8%) patients had a prior stroke. Additionally, 
six (12%) patients had prior deep vein thrombophle- 
bitis (DVT), with pulmonary embolism in three. Of 
the 21 women 14 (67%) had premature menopause. 
Symptoms. indicating the need for vascular sur- 
gical evaluation and treatment included intermittent 
claudication i  47 (92%), ischemic rest pain in 29 
(57%), and tissue loss in 16 (31%) patients. Mean 
ankle/brachial ndexes in the symptomatic l mbs were 
0.59 for those with claudication, 0.47 for those with 
rest pain, and 0.34 for those with tissue loss. The 
distribution of arterial occlusive disease was aorto- 
iliac-femoral in 29 (57%), superficial femoral arte- 
ry-popliteal in 33 (65%), and tibial-pedal in 16 
(31%) patients. Thirteen (26%) had a clinical diag- 
nosis of arterial hypoplasia (small-caliber arteries). 
Twenty (39%) patients had prior lower extremity 
vascular intervention(s) or amputation(s). At the 
time of laboratory evaluation, 13 (25.5%) patients 
were studied less than 3 months after acute lower 
extremity ischemia or vascular surgical procedure. 
The remaining 38 (74.5%) patients were evaluated 
for chronic lower extremity ischemia and either 
underwent operation more than 3 months before 
laboratory evaluation or had never undergone r vas- 
cularization. 
Acute ischemia nd recent vascular surgery was 
associated with a history of myocardial infarction 
(p < 0.05) and DVT (p < 0.05). Thrombocytosis 
(platelet count > 450,000) was associated with 
acute ischemia (p < 0.05) and prior vascular surgical 
procedures (p < 0.05). Overall, 39 (77%) of these 
51 young patients underwent lower extremity revas- 
cularization, and 28 (55%) have required more than 
one vascular procedure. Fourteen (27%) patients 
required major lower extremity amputations, nine 
above-knee and seven below-knee; two patients 
underwent bilateral amputation. Mean follow-up was 
9.5 months (range 1 to 39 months). Seventeen 
patients were lost to follow-up after initial laboratory 
evaluation. Two other (4%) patients have since died. 
Laboratory evaluation. Laboratory abnormali- 
ties were detected in 46 of the 51 patients (90%). At 
initial evaluation, one or more natural anticoagulant 
deficiencies were found in 15 (30%) patients. These 
included deficiencies of antithrombin III in five 
(10%), protein C in eight (16%), protein S in four 
(8%), and heparin cofactor II in two (5%) patients. 
Defective fibrinolytic activity was found in a total of 
29 (59%) of 49 patients tested and included defi- 
ciency of t-PA after venous occlusion in 22 (44%), 
and elevated baseline and postvenous occlusion 
PAI-1 in 29 (59%). Ten (20%) patients had com- 
bined natural anticoagulant and fibrinolytic deficien- 
cies. Elevated Lp(a) was found in 43 (86%) of 50 
patients and was the only abnormality in6; 37 (72%) 
patients had Lp(a) greater than 300 mg/L. Five 
(10%) patients had anticardiolipin antibodies. Five 
patients had no abnormalities. 
Natural anticoagulant deficiencies found during 
initial evaluation were associated with acute ischemia 
(p < 0.01) and recent or remote vascular surgical 
procedures (p < 0.01) (Table II). All patients with 
protein C deficiency had previously undergone vas- 
cular intervention (p < 0.01). Natural anticoagulant 
deficiencies, generally, and protein C deficiency, in 
particular, were associated with an increasing number 
of total vascular procedures per patient (p < 0.01). 
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Table II. Hypercoagulable abnormalities in relation to ischemia nd prior vascular surgical 
interventions in 51 young patients with premature lower extremity atherosclerosis 
Lower extremity ischemia Prior vascular intervention 
Acute Chronic Yes No 
(n = 13) (n = 38) p (n = 20) (n = 31) p 
Natural anticoagulant deft- 61.5% 
ciencies 
Antithrombin III (n = 5) 23.1% 
Protein C (n = 8) 23.1% 
Protein S (n = 4) 15.4% 
Heparin cofactor II (n = 2) 9.1% 
Fibrinolytic abnormalities 61.5% 
Tissue plasminogen activa- 
tory (t-PA) 
Baseline t-PA (n = 14) 25.0% 
20 min venous occlusion (n = 22) 50.0% 
Plasminogen activator inhibitor-I 
(PAI-1) 
Baseline PAL1 (n = 29) 58.3% 
20 min venous occlusion (n = 29) 66.7% 
Elevated Lp (a) (n = 43) 84.6% 
Aaaticardiolipin antibodies (n = 5) 15.5% 
18.4% < 0.01 57.1% 10.0% < 0.01 
5.3% NS 14.3% 6.7% NS 
13.2% NS 38.1% 0% <0.01 
5.4% NS 9.5% 6.9% NS 
3.7% NS 11.1% 0% NS 
68.4% NS 85.7% 53.3% < 0.05 
29.7% NS 33.3% 25.0% NS 
43.2% NS 52.4% 39.3% NS 
59.5% NS 76.2% 46.4% NS 
56.8% NS 76.2% 43.4% NS 
75.7% NS 85.7% 72.4% NS 
8.1% NS 0% 17.2% NS 
Chi-square analysis for trend confirmed the associa- 
tion of natural anticoagulant deficiencies and protein 
C deficiency with an increasing number of total 
vascular procedures per patient (p < 0.03). Both 
natural anticoagulant deficiencies and protein C 
deficiency were also associated with major lower 
extremity amputations (p < 0.01), especially above- 
knee amputation (p < 0.01). Additionally, protein C 
deficiency was associated with a history of DVT 
(p < 0,01). All four patients with protein S defi- 
ciency were black (p < 0.05). Fibrinolytic abnor- 
malities were associated with a history of coronary 
artery disease (p < 0.05) and prior vascular surgical 
procedures (p < 0.05). Elevated Lp(a) was associ- 
ated with both elevated baseline and postvenous 
occlusion PAI-1 (p < 0.05). Lp(a) was unrelated to 
cholesterol and triglyceride l vels. Fibrinogen level 
was available in 20 patients and was unrelated to 
fibrinolytic activity. 
Twenty patients underwent repeat esting after 
their vascular status tabilized to distinguish between 
primary and acquired laboratory abnormalities. Two 
patients were retested for antithrombin III defi- 
ciency; levels in both patients returned to the normal 
range in 3 months. Five patients with protein C 
deficiency were retested; levels in four patients 
normalized in 1 to 36 months. The remaining patient 
had protein C deficiency on three separate occasions 
over 3 years; this patient later died. Two patients 
were retested for protein S deficiency; the level in one 
patient normalized at 1 month, but the level in the 
other emained deficient repeatedly over 3 years. One 
patient with heparin cofactor II deficiency was 
retested and had normalization at 1 month. No 
association between resolution of acquired natural 
anticoagulant deficiencies and acute, postoperative, 
or chronic stages of lower extremity ischemia was 
established. Of 13 patients retested for elevated 
PAI-I, only four (34%) were later found to have had 
normalization. Of 13 patients with elevated Lp(a), 
the levels in 12 (93%) remained elevated at later 
testing. Anticardiolipin antibodies remained present 
in one patient retested at 4 months. 
DISCUSSION 
In terms of demographics, cardiovascular risk 
factors, severity of lower extremity ischemia, and 
response to surgical treatment, the 51 young patients 
prospectively evaluated in this study were similar to 
the earlier retrospectively studied cohort of 109 
patients from this community, s Notably, this pro- 
spective study documented a high incidence of 
cardiovascular risk factors, especially smoking and 
hyperlipidemia, nd identified specific laboratory 
markers associated with atherosclerosis and-throm- 
bosis. These factors may offer some explanation for 
the aggressive nature and poor response to conven- 
tional vascular surgical procedures seen in young 
adults with premature lower extremity ischemia. ~-s 
The implication of these data is that he poor vascular 
JOURNAL OF VASCULAR SURGERY 
Volume 23, Number 1 Levy et al. 41 
surgical results reported in young patients may be 
attributable to a convergence of accelerated athero- 
sclerotic and prothrombotic processes in the lower 
extremity arterial bed, which is disproportionate to 
that typically seen in older patients. 
Past studies have demonstrated that patients with 
defects in regulatory anticoagulant plasma proteins 
are at increased risk for spontaneous arterial, venous, 
and vascular graft thrombosis. 6-14 Unfortunately, the 
current understanding of hypercoagulable states in 
patients with arterial disease, especially studies in- 
volving young patients, remains incomplete and 
worthy of further investigation. In this study of 51 
young patients with premature atherosclerosis, 15 
(30%) were found by prospective laboratory evalu- 
ation to have natural anticoagulant deficiencies. In 
the earlier etrospective survey from this institution, 
only 15% of 109 young patients with lower extremity 
ischemia had a clinical diagnosis of hypercoagulabil- 
ityP Despite generally poor vascular surgical results 
in young patients, the clinical possibility of an 
underlying hypercoagulable state appears to be 
largely underappreciated. 
Other prospective studies have also indicated that 
young patients have a higher incidence of hyperco- 
agulability than the general vascular population. 
Eldrup-Jorgensen t al.6 found one or more natural 
anticoagulant deficiencies in six (33%) of 20 patients 
less than 50 years old with vascular disease. In that 
study 20% were protein S deficiencies, and 15% were 
protein C deficiencies; hypercoagulability was found 
in all four patients with early graft failures. 6Aronson 
et al.7 found coagulation abnormalities in 11 (33%) 
of 37 patients less than 45 years old with vascular 
disease. Only four (9%) of these patients, however, 
had natural anticoagulant deficiencies (three patients 
with protein S and one with antithrombin III 
deficiency). 7 Valentine t al. 8 recently reported natu- 
ral anticoagulant deficiencies in 15 (30%) of 50 
young male patients less than 45 years old with 
vascular disease. Protein C deficiency has been found 
in less than 2% of the general population but is three 
to four times more frequent in young patients with 
unexplained vascular thrombosis. 24Hereditary pro- 
tein S deficiency was recently reported in 8% of 
young patients with arterial disease. 2s On the basis of 
these surprisingly similar observations, it can be 
expected that natural anticoagulant deficiencies will 
be found in approximately one third of young 
patients evaluated for premature lower extremity 
atherosclerosis. 
In contrast, recent series from other vascular 
surgical centers imply that natural anticoagulant 
deficiencies intypical patients with peripheral rterial 
disease are uncommon. 9-~1 Donaldson et al. 9 prospec- 
tively studied hypercoagulability in 158 patients 
drawn from the general vascular population with a 
mean age of 65.4 years (range 30 to 91 years). Fifteen 
(9.5%) of these patients had laboratory abnormali- 
ties, but only seven (4%) had natural anticoagulant 
deficiencies (four patients with protein C, two with 
antithrombin III, and one with protein S defi- 
ciency).9 Tollefson et al.10 reported four patients with 
protein C deficiency and spontaneous arterial throm- 
bosis. Eason et al. H also treated four patients with 
natural anticoagulant deficiencies (two with protein 
S, one with protein C, and one with combined 
protein S and C deficiency). Overall, these data 
suggest hat protein C deficiency may be the most 
frequent abnormality inpatients with vascular disease 
and natural anticoagulant deficiencies and especially 
those patients with thrombotic events. 6~2 
Information regarding the role of fibrinolytic 
activity in patients undergoing peripheral vascular 
surgery isunfortunately lacking. In this study, 44% of 
the 49 patients tested had a deficiency of stimulated 
t-PA, and 59% had abnormally elevated baseline and 
stimulated PAI-1. The association of impaired fibri- 
nolysis and thrombotic omplications caused by 
elevated PAI-1 has been reported. 26 It has been 
previously shown that fibrinolytic deficiencies can 
occur with arterial and venous thrombosis and early 
lower extremity bypass failures? 7 Elevated PAI-1 has 
been related to other cardiovascular risk factors uch 
as diabetes, hypertension, and hyperlipidemia. 26,27 
Laboratory models suggest the presence of an 
intravascular p ofibrinolytic response to conditions 
of ischemia or hypoxia. 28 This protective mechanism 
may be impaired in many young patients with 
premature lower extremity ischemia. At least 10% of 
the patients in this study had combined natural 
coagulant deficiencies and inhibition of fibrinolysis. 
Further studies are needed to define better the role of 
fibrinolytic activation and inhibition in patients of all 
ages with peripheral arterial occlusive disease. 
Of the 51 young patients in this study, 86% had 
elevated Lp(a). Also note that 72% still had elevated 
Lp(a) with the less stringent but more widely 
accepted value of 300 mg/L as the upper limit of 
normal. Valentine t al.14 recently demonstrated that 
elevated Lp(a) was an independent risk factor for 
premature atherosclerosis in young white men. 
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High-levels of Lp(a) have been shown previously to 
be an independent risk factor for coronary artery 
disease and early aortocoronary vein graft occlu- 
sion. 13 Additionally, elevated Lp(a) in this study was 
related to baseline and stimulated elevations in 
PAI-1. Cellular and molecular mechanisms linking 
Lp(a) and competitive inhibition of fibrinolysis have 
been proposed because of structural homology be- 
tween the apolipoprotein side-chains of Lp(a) and 
plasminogen. ~3 
Earlier studies in patients with vascular disease 
have not attempted the difficult task of distinguishing 
between primary (congenital or familial) and ac- 
quired (secondary) natural anticoagulant deficiencies. 
In this study, 20% of natural anticoagulant deficien- 
cies retested were persistent on repeated tests over 
several years under stable conditions suggesting that 
these two were primary deficiencies. It was found that 
the remaining 80% that were retested later normal- 
ized, indicating that they were acquired deficiencies. 
It has been previously shown that plasma levels of 
natural anticoagulants can be adversely affected by 
clinical circumstances, especially after acute arterial or 
venous thrombotic events and major vascular surgical 
procedures# Acquired natural anticoagulant defi- 
ciencies may be clinically relevant, but caution must 
be exercised when interpreting such abnormalities as 
primary without retesting under stable conditions. In 
contrast, abnormalities of fibrinolysis, Lp(a), and 
anticardiolipin antibodies were more persistent over 
time. No association between acquired hypercoagu- 
lability and acute ischemia or recent surgery was 
established. There were too few patients in this study 
to draw conclusions with regard to thrombotic 
implications of anticardiolipin antibodies. 
These data bring us closer to an understanding of 
the virulence associated with premature atheroscle- 
rosis. In this study, observed laboratory abnormali- 
ties were strongly associated with severe ischemia, 
early bypass failure, multiple revascularization at- 
tempts, and amputation. It was shown that patients 
with premature atherosclerosis are at an exceptional 
risk because of a high incidence of cardiovascular risk 
factors, especially elevated Lp(a). Additionally, they 
are at an increased risk of thrombotic complications 
because of hypercoagulability associated with natural 
anticoagulant deficiencies and hypofibrinolysis. Fu- 
ture clinical efforts should be directed toward aggres- 
sive risk factor modification and reversal of observed 
laboratory abnormalities by appropriate use of anti- 
coagulants, antiplatelet agents, semisynthetic estro- 
gens and androgens, and corticosteroids. Clinical 
trials are currently in progress testing the effective- 
ness of these therapies as adjuncts to standard vascular 
surgical options. 
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D ISCUSSION 
Dr. Magruder C. Donaldson (Boston, Mass.). We are 
all aware that patients under the age of 50 with manifes- 
tations of peripheral rterial occlusive disease are among the 
most challenging to treat. Among others grappling with 
this fact over the years, Levy et al. s presented a series of 109 
young patients studied retrospectively, documenting at 
best a 14% incidence of hypercoagulable states. Un- 
daunted, they have pushed ahead since then with this 
prospective study, taking advantage of the increasing 
variety of useful aboratory probes into the multiple facets 
of hypercoagulability. With this more systematic and 
sensitive approach, they have uncovered specific prothrom- 
botic abnormalities in no less than 46 of 51 consecutive 
patients. Most novel is their finding of impaired fibrinolysis 
in the form of inadequate stimulation of tissue plasminogen 
activator secretion in 45% of patients and elevated baseline 
or stimulated levels of plasminogen activator inhibitor in 
59% of subj&ts. Elevated levels of Lp(a) were present in 
fully 86% of patients, albeit with 11 or 20 mg/dl rather 
than the more standard 30 mg/dl mark as the upper limit 
of normal. Interestingly, in addition to contributing to 
atherosclerotic plaque, Lp(a) has been found by others to 
retard t-PA activation of plasminogen, and the authors 
confirmed an association between elevated Lp(a) and 
increased PAI-1 activity. These findings strongly suggest 
that the most critical problem in many of these young 
people is hypofibrinolysis rather than hypercoagulability. 
What proportion of your patients with elevated Lp(a) 
levels had values greater than 30 mg/dl, which is the upper 
limit of normal in other laboratories, including our own? 
And given their overall experience with this compli- 
cated group, many members of which had multiple markers 
of hypercoagulability, would the authors care to elaborate 
on a possible unifying pathologic mechanism behind the 
fundamental abnormality at the arterial wall and blood 
interface? 
Though incomplete, these data comparing patients 
with acute and chronic conditions and follow-up assays in 
20 of the original 51 subjects suggests that fibrinolytic 
abnormalities and Lp(a) elevation remain present with 
time, perhaps in association with other chronic stimuli such 
as smoking and genetics. On the other hand, efficiency in 
natural anticoagulants such as antithrombin III and protein 
C appear elatively evanescent, possibly in association with 
acute disease or surgical trauma. Despite this fact, the 
authors found an unusually strong correlation between 
natural anticoagulant deficiency and clinical thrombosis. 
Did the timing of the thrombotic events in these 
patients fit convincingly with the presumed flux in natural 
anticoagulants? And if so, is the association strong enough 
to support astrategy of preoperative screening and targeted 
perioperative factor epletion or anticoagulation to protect 
this subgroup? 
In a more general, practical vein, given these new 
insights into possible mechanisms of disaster, can you 
speculate on any adjunctive therapies, perhaps directed at 
impaired fibrinolysis, which might supplement sole reli- 
ance on antiplatelet and anticoagulant agents? 
It has been fascinating to see our understanding of 
hypercoagulability emerge over the last 15 years, and we are 
indebted to Dr. Levy and his colleagues for this unique 
prospective study of a very complicated but fundamental 
problem facing us all. 
Dr. Pavel J. Levy. With regard to the first question of 
Lp(a), normal values were > 30 mg/dL The reason we used 
the lower values was because, while performing the study 
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and analyzing the data, our hematology laboratory was 
performing normal controls and found that the normal 
levels should be lower. That was why we reported 86%. 
However, when we initially evaluated the data, using 30 
mg/dl and up, we had 75% of hyperlipoproteinemia, which 
indicates that the increase in lowering the normal value was 
not significant. 
With regard to the second question of unifying 
hypercoagulable mechanisms in patients with premature 
atherosclerosis, the only thing we can extrapolate from our 
data and previously published series is that there indeed is 
correlation between atherosclerosis and thrombosis, there- 
fore I used the term atherothrombosis. We believe that 
markers of endothelial cell perturbation are the key factor 
in atherothrombogenesis andatherothrombosis itself. 
To the third question about the flux of natural anti- 
coagulants, we showed that the levels of about 80% of 
patients who were studied serially with elevated natural 
anticoagulant became normal during the follow-up period. 
Unfortunately, one of the limitations of our study is that we 
could not perform serial studies on all patients as planned 
initially. Of two patients who continued to have a 
deficiency of protein C, one of them remained in the 
so-called "acute stage" and eventually died. The other 
patient had chronic ischemia during the follow-up because 
of deficient anticoagulants. 
With regard to the final question about what would be 
our proposal for screening of premature atherosclerosis in 
young patients, we believe that screening for natural 
anticoagulants may be very important in particular groups 
of patients, especially those who had had prior history of 
venous thromboembolism, as did six patients in our group 
who had a family history of venous thromboembolism or 
repeated thrombotic events. We definitely would study 
those patients for natural anticoagulants. From our study 
and from the literature regarding heparin cofactor II, it 
probably will be unnecessary. 
We don't believe that anticoagulant antibodies have 
any scientific importance in evaluating the patients, al- 
though there are several series that indicate an extremely 
high prevalence of patients with venous thrombosis receiv- 
ing anticoagulants. However, we definitely would advise 
screening the patient for Lp(a). 
Dr. Charles O. Brantigan (Denver, Colo.). It seems 
that a significant number of patients in this series had acute 
arterial ischemia, and, in the presence of major vessel 
thrombosis, many coagulation tests, as a result are disorder 
of the thrombosis. How do we know in this study that 
we're studying the chicken instead of the egg? 
Dr. Levy. Twenty-five percent of patients in our study 
indeed had either acute arterial ischemia or were studied 
within less than 3 months after surgery, being operated 
sometimes for chronic ischemia. So those were only one 
fourth of the patients. These patients did not differ 
statistically from patients with chronic ischemia, with 
regard to decreased fibrinolytic activity and the prevalence 
of Lp(a) and anticoagulant antibodies. Some of these 
hypofibrinolytic thctors, such as PAI-1, could be acute 
phase reactants; however, we didn't find any difference 
between patients with acute and chronic ischemia. I would 
like to stress the importance of studying patients for 
possible hypercoagulability divided into acute and chronic 
stages. 
Mr. H. H, G. Eastcott (London, United Kingdom). 
That was a very interesting survey of a problem that we are 
going to see more of. We have seen something like this in 
Europe, particularly with Arab patients. Colleagues in 
Lisbon and in Porto have described a similar condition, 
which has one particular feature on investigation that is not 
in your report, and that is the red blood cell sedimentation 
rate. The patients we have seen mostly had raised sedimen- 
tation rate. And in association with this, a peculiarity of the 
lesion itself, which although it was clearly atheromatous 
and although this is the age group for Buerger's disease, 
your patient in no way resembled that condition except for 
their age and history of smoking. But the chief feature of 
this lesion in the Portuguese and the Arab patients was its 
adherence. The adventitia was strongly adherent o the 
surrounding tissues and the endarterectomy, or the grafting 
procedure was unusually difficult. 
I was very interested that you had five cases of the 
antiphospholipid syndrome. Medicolegally vascular sur- 
geons may plead this deficiency as a cause for unexpected 
failure after vascular econstruction. We are told that it's 
rather uncommon in arterial cases and is seen more often 
with venous thrombosis. I'm interested to see that no fewer 
than five of your cases had this. 
Dr. Erwin A. Cohen (Cheltenham, Pa.). Over the 
years, I've operated on some young women in their 20s. 
The historical background was birth control pills and heavy 
smoking. I have not seen it recently. ! don't know whether 
it's because they've changed the birth control pill dosage. 
We had not, at that time, studied them tbr hypercoagulable 
states. I wonder if you have any experience with this group 
of patients? 
Dr. Levy, We did find a very high prevalence of young 
women; however, it appears that most of the women had 
premature menopause atthe time that they were tested. We 
don't have clear medical history of use of birth control pills; 
however, recently, there were several clinical studies about 
association between birth control pills and antithrombin 
III deficiency. So, if a relatively high prevalence of natural 
anticoagulants is found at initial study and almost half of 
our patients are women, this brings us to an interesting 
point that we should more thoroughly ask about birth 
control pills, because then we may find unexpectedly more 
arterial diseases, not only venous. - 
Dr. Bo Risberg (Maim6, Sweden). We studied 
patients with acute embolic or thrombotic ischemia within 
3 days of onset. When those patients arrived at the hospital, 
we found that if they had reduced single-chain urokinase 
plasminogen activator levels or if they had high Lp(a), 
those were the patients that eventually died. That points 
out important connections between fibrinolysis and death. 
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Now, Lp(a) competitively inhibits the plasminogen bind- 
ing to fibrin and that's why the fibrinolytic system can be 
inhibited by high Lp(a). 
We know that there are at least 15 isoforms of Lp(a) 
with different fibrin binding. So if we have isoforms that 
bind very much to fibrin, we may have a more pronounced 
effect on the fibrinolytic system. Do you have any 
information on those isoforms? 
Dr. Levy. Two of our patients died; however, clearly 
there was an association between hyperfibrinolysis and 
recurrent myocardial infarction in patients younger than 
age 45. And that's exactly the group of our patients, bearing 
in mind that two thirds of our patients had a history of 
coronary artery disease. 
With regard to the question about 15 isoforms and 
Lp(a), I do not have information. We will need to evaluate 
more thoroughly the association of Lp(a) and different 
findings from the basic sciences about association with 
premature atherosclerosis. 
Dr. Peter M. Kasprzan (Regensburg, Germany). Can 
you comment on any possible influence of medical 
treatment on your data, especially in patients with arteri- 
alization before your initial investigation? 
Dr. Levy. Regarding the medical treatment, most of 
the patients who came to our attention were not treated 
medically except with aspirin. However, because we started 
to notice a high prevalence ofhypercoagulability markers in 
our patients, we started with noncontrolled, nonrandom- 
ized treatment of some of our patients with low-dose or 
full-dose warfarin (Coumadin). 
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